Anti-IL5/IL5R (reslizumab, mepolizumab, benralizumab) | N = 42 | Anti-IgE (omalizumab) | N = 22 | |||
---|---|---|---|---|---|---|
Baseline | Change | P | Baseline | Change | P | |
Sick leaves ** | 0.93 (0–6. SD 1.72) | −0.58 (−6–6. SD 1.86) | 0.037 | 0.59 (0–4. SD 1.03) | −0.14 (−3–11. SD 1.18) | 0.602 |
Total number of exacerbation events *** | 7.57 (1–26. SD 5.59) | −4.43 (−22–13. SD 6.24) | 4.79 e− 05 | 4.68 (0–11. SD 3.40) | −1.50 (− 7–21. SD 5.55) | 0.006 |
Mean FEV1 (litres) | 2.27 (1.0–4.2. SD 0.78) | 0.17 (− 0.5–1.3. SD 0.41) | 0.317 | 2.83 (1.5–4.2. SD 0.86) | 0.05 (− 0.6–1.3. SD 0.54) | 0.720 |